Integra LifeSciences Holdings Corporation filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 8, 2026. The filing discloses that the company has furnished an updated investor presentation to be used in discussions with existing and prospective lenders. The purpose of these materials is to support the company's previously disclosed plans to refinance its outstanding senior credit facility in 2026.
The attached presentation, dated September 8, 2026, is restricted to qualified institutional buyers (QIBs) and non-U.S. persons. It outlines the company's business segments, which include Specialty Surgery and Tissue Reconstruction. The document highlights that 2026 is viewed as a key inflection period for the company as it progresses through FDA-mandated manufacturing and quality system remediations.
Key operational milestones mentioned in the presentation include:
- The completion of all warning letter commitments is expected to be finished in 2026.
- The SurgiMend product line is expected to relaunch in the fourth quarter of 2026.
- A new state-of-the-art manufacturing site in Braintree, Massachusetts, became operational in the second quarter of 2026, with commercial revenue generation expected in the fourth quarter of 2026.
Financial highlights for the trailing 12 months through June 30, 2026, include:
- Revenue of $1.648 billion, representing a 1.6% year-over-year increase.
- Adjusted EBITDA of $337 million, an 11.8% increase year-over-year, resulting in a 20.5% adjusted EBITDA margin.
- Year-over-year growth in free cash flow of $57 million.
